Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.41 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.41 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205947 | 0.84 | PTGS1 (0.58) | PTGS1KDM4EALDH1A1TGFBR1PTGS2 | |
| SCHEMBL12361519 | 0.79 | PTGS1 (0.52) | PTGS1KDM4EALDH1A1PTGS2SCN9A | |
| SCHEMBL28157524 | 0.78 | PTGS1 (0.68) | PTGS1KDM4EALDH1A1PTGS2PDPK1 | |
| SCHEMBL12361500 | 0.78 | ALDH1A1 (0.56) | PTGS1KDM4EALDH1A1TGFBR1SCN9A | |
| SCHEMBL3756976 | 0.78 | ALDH1A1 (0.65) | PTGS1KDM4EALDH1A1TGFBR1PTGS2 | |
| SCHEMBL3756974 | 0.77 | PTGS1 (0.50) | PTGS1KDM4EALDH1A1TGFBR1PTGS2 | |
| SCHEMBL3756968 | 0.77 | ALDH1A1 (0.55) | PTGS1KDM4EALDH1A1TGFBR1PTGS2 | |
| SCHEMBL537395 | 0.76 | PTGS1 (0.65) | PTGS1KDM4EALDH1A1PTGS2PDPK1 | |
| SCHEMBL7570850 | 0.76 | PTGS1 (0.65) | PTGS1KDM4EALDH1A1PTGS2PDPK1 | |
| SCHEMBL1012734 | 0.75 | PTGS1 (0.63) | PTGS1KDM4EALDH1A1PTGS2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030119748-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | disclosed |
| EP-0920444-B1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS INC (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6489353-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM DISORDERS | IDUN PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020025935-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| EP-1159291-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYLCARBONYLDIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001000658-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYLCARBONYLDIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| US-5877197-A | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 1999-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025935-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, CASP1, IAPP | PTGS1 2160/4885KDM4E 2905/4885ALDH1A1 4493/4885 |
| US-20030119748-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | CASP3, CASP1, IAPP | PTGS1 2147/4885KDM4E 2929/4885ALDH1A1 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.